Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

HER2-Targeting Antibody-Drug Conjugate in Advanced Urothelial Carcinoma

By: Kelly M. Hennessey, PhD
Posted: Thursday, December 10, 2020

A recent study conducted by Jun Guo, MD, of Peking University Cancer Hospital & Institute, Beijing, China, and colleagues assessed the efficacy and safety of RC48-ADC—an HER2-targeting antibody-drug conjugate with monomethyl auristatin E—in patients with HER2-positive locally advanced or metastatic urothelial carcinoma. They found that patients achieved higher objective response rates and progression-free survival with the novel agent than other immune checkpoint inhibitors. Their results were published in Clinical Cancer Research.

This phase II, open-label, multicenter, single-arm clinical trial examined the objective response rate of RC48-ADC in patients with HER2-positive locally advanced or metastatic urothelial carcinoma who previously failed to respond to prior systemic chemotherapy. A total of 43 eligible patients were treated with RC48-ADC at 2.0 mg/kg over 30 to 90 minutes once every 2 weeks until disease progression, intolerable toxicity, death, or withdrawal of consent. The treatment dose was modified and interrupted for up to 28 days in patients experiencing treatment-related adverse events until they resolved to grade 0/1 or baseline. The median follow-up at the cutoff date was 20.3 months.

The objective response rate was 51.2% (n = 22), and 39.5% (n = 17) experienced stable disease as best response. In 88.4% of patients (n = 38), tumor shrinkage was observed. The median duration of response was 6.9 months, and progression-free survival was observed in 59.1% of patients at 6 months. Median overall survival was 13.9 months. Patients with higher HER2 expression achieved higher objective response rates than patients with lower HER2 expression.

“The objective response rate and progression-free survival of this trial show disease efficacy for HER2-expressing metastatic urothelial cancer,” explained the researchers. “RC48-ADC has the potential to become a treatment option for metastatic urothelial carcinoma with HER2 overexpression,” they concluded.

Disclosure: For full disclosures of the study authors, visit clincancerres.aacrjournals.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.